Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2012-12-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cca.2012.08.005PMID 22985537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Support vector machine

  2013cited by this paper
• Nonalcoholic fatty liver disease and bariatric surgery

  2012cited by this paper
• Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease.

  2012cited by this paper
• Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.

  2011cited by this paper
• Non‐invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis

  2011cited by this paper
• Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

  2011cited by this paper
• Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis.

  2011cited by this paper
• Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration

  2011cited by this paper
• Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study

  2011cited by this paper
• Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease

  2011cited by this paper
• Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic

  2011cited by this paper
• Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease.

  2011cited by this paper
• Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease

  2011cited by this paper
• Toward a biochemical diagnosis of NASH: insights from pathophysiology for distinguishing simple steatosis from steatohepatitis.

  2011cited by this paper
• An apoptosis panel for nonalcoholic steatohepatitis diagnosis.

  2011cited by this paper
• A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis

  2011cited by this paper
• Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease.

  2011cited by this paper
• Nonalcoholic steatohepatitis: risk factors and diagnosis

  2010cited by this paper
• Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

  2010cited by this paper
• Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease

  2010cited by this paper
• Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis

  2010cited by this paper
• Non-invasive diagnostic tests for non-alcoholic fatty liver disease.

  2010cited by this paper
• Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.

  2009cited by this paper
• A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

  2008cited by this paper
• Support Vector Machines and Kernels for Computational Biology

  2008cited by this paper
• Nonalcoholic Steatohepatitis and the Metabolic Syndrome

  2008cited by this paper
• Diagnosis and therapy of nonalcoholic steatohepatitis.

  2008cited by this paper
• Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

  2007cited by this paper
• Machine learning methods for predictive proteomics

  2007cited by this paper
• Urinary nucleosides based potential biomarker selection by support vector machine for bladder cancer recognition.

  2007cited by this paper
• Support vector machine applications in bioinformatics.

  2003cited by this paper

• Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions

  2025cites this paper
• The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model

  2022cites this paper
• Artificial Intelligence Applications in Clinical Chemistry.

  2022cites this paper
• Ultrasound Image Computerized Analysis for Non-invasive Quantitative Evaluation of Hepatic Fibrosis.

  2021cites this paper
• Applications of machine learning in the chemical pathology laboratory

  2021cites this paper
• Hepatic FGF21 is Under the Regulation of the Canonical Wnt Signaling Pathway by Yasaman Badakhshi A thesis submitted in conformity with the requirements

  2020cites this paper
• The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease

  2020cites this paper
• Biomarkers of Non Alcoholic Steatohepatitis: a systematic review and meta-analysis

  2019cites this paper
• Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.

  2019cites this paper
• Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta‐analysis

  2017cites this paper
• Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis

  2017cites this paper
• Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

  2017influential citation
• Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease

  2016cites this paper
• The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.

  2015cites this paper
• Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

  2015cites this paper
• (Cleaved) CK18 serum and tissue expression levels differentiate acute HCV reinfection from acute rejection in liver allografts

  2015cites this paper
• Assessment of machine-learning techniques on large pathology data sets to address assay redundancy in routine liver function test profiles

  2015cites this paper
• Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers

  2014cites this paper
• A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease

  2014cites this paper